An overview on the diagnosis and approaches in pharmacological management of Parkinson’s disease

Abstract

Parkinson’s disease (PD) might be a mutual neurodegenerative disease considered by a movement disorder containing rest tremor, bradykinesia, rigidity, and postural instability, and second-leading reason of dementia and is categorized by an advanced loss of dopaminergic neurons within the neural structure alongside the occurrence of intraneuronal α-synuclein-positive enclosures. PD is identified where bradykinesia happens along with rigidity or tremor within the existence of supporting features. The diagnosis is clinical, and a spotlight should be paid to omission criteria on behalf of an auxiliary diagnosis and to ‘red flag’ structures. There is no cure or disease amending treatment for PD, and hence the rate of advance is variable. The foremost operative symptomatic treatment relics levodopa, which has greater benefits for quality of life in early PD associated with other therapies.